- Home
- TRX vs HOWL Comparison
TRX vs HOWL Comparison
Compare TRX & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TRX | HOWL |
|---|---|---|
| Founded | 1990 | 2017 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 228.9M | 64.5M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | TRX | HOWL |
|---|---|---|
| Price | $1.01 | $0.63 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $1.25 | ★ $6.50 |
| AVG Volume (30 Days) | ★ 1.7M | 831.2K |
| Earning Date | 01-13-2026 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.00 | N/A |
| Revenue | ★ $57,613,000.00 | N/A |
| Revenue This Year | $93.43 | N/A |
| Revenue Next Year | $44.56 | N/A |
| P/E Ratio | $394.10 | ★ N/A |
| Revenue Growth | ★ 39.98 | N/A |
| 52 Week Low | $0.27 | $0.56 |
| 52 Week High | $0.97 | $2.38 |
Technical Indicators
Market Signals| Indicator | TRX | HOWL |
|---|---|---|
| Relative Strength Index (RSI) | 75.54 | 31.82 |
| Support Level | $0.91 | $0.61 |
| Resistance Level | $0.89 | $0.74 |
| Average True Range (ATR) | 0.05 | 0.09 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 100.00 | 12.26 |
Price Performance
Historical ComparisonAbout TRX TRX Gold Corporation
TRX Gold Corp is a mineral resource company. It is engaged in the acquisition of interests and the exploration of natural resource properties. Its mineral properties are located in the United Republic of Tanzania. The company's main area of interest has been in the exploration and development of gold properties. It is focused on the Buckreef Gold Project which comprises five prospects, namely Buckreef, Bingwa, Tembo, Eastern Porphyry, and Buziba.
About HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.